Secukinumab: In psoriasis and beyond

Abstract

Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris, pyoderma gangrenosum, lichen planus, and Behçet’s disease. This review will throw light on secukinumab’s utility in psoriasis, as well as other dermatologic conditions.

Keywords

• hidradenitis suppurativa
• off-label dermatologic indications
• psoriasis
• secukinumab